22 January 2021
EMA/CHMP/10194/2021
EMEA/H/C/001165

Public statement

Clopidogrel ratiopharm GmbH

Withdrawal of the marketing authorisation in the European Union

On 13 January 2020, the European Commission withdrew the marketing authorisation for Clopidogrel ratiopharm GmbH (clopidogrel) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Archie Samuel s.r.o., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Clopidogrel ratiopharm GmbH was granted marketing authorisation in the EU on 28 July 2009 for prevention of atherothrombotic events. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014.

Clopidogrel ratiopharm GmbH is a generic medicine of Plavix. There are other generic medicinal products of Plavix authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Clopidogrel ratiopharm GmbH will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union